case_images: PMC10064474_01
case_images: (a) Confluent pink patches on the upper extremities with islands of sparing over the antecubital fossae and (b) confluent pink patches on the lower extremities with islands of sparing over the popliteal fossae.
case_images: 10.1177_2050313X231160927-fig1.jpg
case_images: PMC10064474_01_10.1177_2050313X231160927-fig1.jpg
case_images: fig1-2050313X231160927
case_images: She initially had significant improvement with much thinner, less erythematous plaques on her trunk and extremities, but still involving ~60% body surface area (BSA; Figure 1(a) and (b)).
case_images: (a) Pink confluent scaly plaques on the upper extremities with islands of sparing, (b) improvement following 14 days of treatment with upadacitinib, and (c) improvement following 6 weeks of treatment with upadacitinib.
case_images: 10.1177_2050313X231160927-fig2.jpg
case_images: PMC10064474_01_10.1177_2050313X231160927-fig2.jpg
case_images: fig2-2050313X231160927
case_images: The drug was subsequently discontinued (Figures 2(a), 3(a), and 4(a)). She was reassessed at day 14 of treatment and found to have a 25% improvement (Figures 2(b), 3(b), and 4(b)). By week 6 of treatment with upadacitinib, she had a 65% overall improvement in BSA involvement and thinner plaques in keeping with her initial response to ustekinumab (Figures 2(c) and 3(c)).
case_images: (a) Red confluent scaly plaques on the lower extremities with islands of sparing, (b) improvement following 14 days of treatment with upadacitinib, and (c) near-complete resolution following 6 weeks of treatment with upadacitinib.
case_images: 10.1177_2050313X231160927-fig3.jpg
case_images: PMC10064474_01_10.1177_2050313X231160927-fig3.jpg
case_images: fig3-2050313X231160927
case_images: The drug was subsequently discontinued (Figures 2(a), 3(a), and 4(a)). She was reassessed at day 14 of treatment and found to have a 25% improvement (Figures 2(b), 3(b), and 4(b)).